X4 Pharmaceuticals (XFOR) Retained Earnings (2017 - 2025)
X4 Pharmaceuticals (XFOR) posted Retained Earnings of -$109000.0 for Q4 2025, up 99.98% on a QoQ basis from -$570.6 million in Q3 2025, and up 99.98% year-over-year from -$54505.8 in Q4 2024.
X4 Pharmaceuticals (XFOR) Retained Earnings (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals' Retained Earnings history runs 9 years deep, the most recent figure standing at -$109000.0 for Q4 2025.
- Quarterly Retained Earnings rose 99.98% year-over-year to -$109000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$109000.0 (up 99.98% YoY) and the FY2025 annual result came in at -$109000.0, up 99.98% from the prior year.
- Retained Earnings was -$109000.0 for Q4 2025 at X4 Pharmaceuticals, up from -$570.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $43.6 million in Q4 2022 and bottomed at -$570.6 million in Q3 2025.
- A 5-year average of -$312.6 million and a median of -$374.2 million in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 36738.66% — and 2024, when it plunged 368639.5%.
- X4 Pharmaceuticals' Retained Earnings stood at -$119000.0 in 2021, then jumped by 36738.66% to $43.6 million in 2022, then plunged by 1196.11% to -$477.9 million in 2023, then fell by 7.84% to -$515.4 million in 2024, then soared by 99.98% to -$109000.0 in 2025.
- Business Quant data shows XFOR's Retained Earnings at -$109000.0 in Q4 2025, -$570.6 million in Q3 2025, and -$540.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -622,000.00 |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | -109,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -109,000.00 |
| Sep 30, 2025 | -570.60 Mn |
| Jun 30, 2025 | -540.80 Mn |
| Mar 31, 2025 | -515.07 Mn |
| Dec 31, 2024 | -515.36 Mn |
| Sep 30, 2024 | -475.50 Mn |
| Jun 30, 2024 | -438.80 Mn |
| Mar 31, 2024 | -529.70 Mn |
| Dec 31, 2023 | -477.91 Mn |
| Sep 30, 2023 | -458.78 Mn |
| Jun 30, 2023 | -119,000.00 |
| Mar 31, 2023 | -400.80 Mn |
| Dec 31, 2022 | 43.60 Mn |
| Sep 30, 2022 | -347.63 Mn |
| Jun 30, 2022 | -326.05 Mn |
| Mar 31, 2022 | -119,000.00 |
| Dec 31, 2021 | -119,000.00 |
| Sep 30, 2021 | -252.66 Mn |
| Jun 30, 2021 | -232.49 Mn |
| Mar 31, 2021 | -212.85 Mn |